,~f~122 Me, h<ai .%'u'n¢¢ Bmhhng I. 17u. t 'mt,'r~m ,,o tlia htk'au tied. at S('tr~) There is a strong association bctmeen certain angiographic and functional abnormalities and the development of ventricular fibrillation and recurrent ventricular fibrillation. In recent yea~. medical attention has been focu.~d upon identifying patients is+ha are vulnerable to the development of lifethreatening arrh,,lhmias. Thus. suni+'ors of myocardial infarction and that identifiable segment of the asymptomatic population with an ominous risk profile are demonstrably at very high risk of sudden death with at least t~o-thlrd,, of the deaths occurring in the first hour.
for tlw prerentum o.f vemncular fibrillation. This article discusses the importmwe oft the predmical phase of drug development in an attempt to flocus on those electrophysiologicai mechan[~nts which superimpo'e upon a wdnerable mvocardium thus leading to, the onset o] ledtM arrhythmias, it is agab~st this background that potentially usehd pharma( oh~gical inten,entions must be as~ssed ifl specific therapy for die prevention ot sudden coronao, death is to become a reality.

What seems to be the content?
The morbid statistics for the United States alone would sug,_-est that there are 400000 victims each year who succumb to sudden coronary death. The very suddenness of, and the electrocardiographic observations prior to or accompanying the fatal event, lead to the assumption that cardiac arrhythmias are the cause of death, either ventricular arrest or ventricular fibrillation, with the majority of patients having underlying heart disease. Mobile coronary care units and rapid response emergency systems have been developed as an approach to aiding ~ictims of out-ofhospital ventricular fibrillation and the results of such efforts at resuscitation have demonstrated that many individuals can be returned to a productive lit'e, although the continued pre~nce of their underlying coronary artery di~ase make them vulnerable to a subsequent event in which lethal arrhythmias may develop suddenly and unexpectedly. There is sufficient clinical evidence to' indicate that the majority of episodes of ventricular fibrillation are 'primary" dysrhythmic events and not secondary to acute myocardial infarction.
There is a strong association bctmeen certain angiographic and functional abnormalities and the development of ventricular fibrillation and recurrent ventricular fibrillation. In recent yea~. medical attention has been focu.~d upon identifying patients is+ha are vulnerable to the development of lifethreatening arrh,,lhmias. Thus. suni+'ors of myocardial infarction and that identifiable segment of the asymptomatic population with an ominous risk profile are demonstrably at very high risk of sudden death with at least t~o-thlrd,, of the deaths occurring in the first hour.
If an impact is to be made upon the high mortality due to sudden coronar~ deatl,., it must depend upon the recognitiun and treatment of those at risk. with the goal of preventing tentricular fibrillation bv a prophylactic theraix.'utic regimen.
Present status or i~mnaeologk~ therap?
A comprehensive review of the pharmacological, electrophysiological and clinical applications of many of the newer, potentially useful, anti-arrhythmic agents has appeared recently t. Despite After M) months, the control group had a u ~,++ monahtx as compared with " II + , ,t~+on~ propranolol-treated patients, thus +up-porting the concept thal mortalitx in the post-myocardial infarct patient carl Ix" reduced +~,ith the institut:on of appropnate therap) An earlier. Nor~egmn Mu!ticemer Trial mith the ~-receptor blocking agent, timolol, demonstrated a potential benefit in reducing the rate at reinfarctlon and the incidence of ,,uddcn death m patients m the tx~st-ho',pit,d pha,~ t,f mx t~:ardtal infarction.
At present, it t+~ s,llC It+ co[ICttlde that there is uncerl+tintx rt.'l~+irdiflg the ntcchu,,ism l+x which ~3-adrcncrgic recopter blt~.-king drugs exert their antsarrh)tnmlc effects in the i~'hemiealh injured heart and +~.+hether or not the~.
agent.~ tan dccream the inctdcnct: of sudden coromtrv death in all patients at risk of experie:tcing a lethal arrh+lhmic event.
The potential implications of them studies are significant in ;hat they indicate that pharmacological inter~ell-tions can prott.~ct the i~hemic heart against the sudden onset of ventricular fibrillation, thus allo~lng more time for the institution of medical assistance. However. the interruption of adrencrgic support to the heart may not be without hazard in those patients who require a degree of cardiac inotropic and chronotropic stimulus during the acute phase of myocardial infarction. Such patients may be subjected to a higher incidence of cardiogenic shock and bradyarrhythmias. Furthermore, 13-adrenergic receptor blockade might preclude the successful use of inotropic agents, such as norepinephrine, dopamine, dobutamine, etc. Other limitations to the use ~f 13-adrenergic receptor blocking agents would be in those patients with obstructive airway disease and in those with heart failure.
Those post-myocardial infarction patients who are not considered to be suitable candidates for the administration of IS-receptor blocking agents could have other available anti-arrhythmic dru~ administered but. unfortunately, they too are limited in their application because of toxicity as,~yziated with their long-term use. An important fact to recognize is that. despite their demonstrated efficacy as anti-arrhythmic drugs, oarrently available agents and many of the newer drugs under clinical investigation have not been shown to be effective in the prevention of sudden coronary death. Furthermore. the effectiveness of a chronically administered drug in protecting the ambulatoD' patient from sudden coronary death can not be predicted from short-term observations made on hospitalized patients with acute myocardial infarction, since there are no reasons to believe that the electrophysiological disturbances leading to ventricutar fibrillation are the same in both situation~.
May et ai. ~ recently reviewed the results of 14 clinical trials involfing 3 6Z ~, patients with documented myocardial infarction who were treated with one of four anti-arrh~ahmic drugs: quinidine. procainamide, disopyramide or lidocaine. Despite t.he fact that each agent has :~een reported to suppress ventricular arrhvthmias in the acute phase of myocardial infarction, and lidocaine may reduce ~he incidence of in-hospital ventricular fibrillattion, not one of the trials has demonstrated that suppression of ventricular premature beats is accompanied by a statistically significant reduction in overall mortality.
~ tes~ procedor~s for the dinical evaluation of
Electrophysiological abnormalities can be demonstrated in a large majority of patients who have sunvived an episode ot out-of-hospital cardiac an'est not associated with acute myocardial infarction. Programmed electrical stimulation is capable of eliciting ventricular tachycardias in most of these patients, suggesting the continued presence of an electrically unstable myocardial substrate. On the other hand, electrically inducible ventricular tachycardia is rarely, if eveL observed in patients who do not have structural hear~ di~ase. thus illustrating the importance of a vulnerable substrate for the development of a re-entrant ta,chyarrhythmia. The provocative testing procedure of programmed electrical stimulation has been applied to the evaluation of drug treatment regimens in patients with recurrent ventricular tachyarrhythmias. The use of an electrophysiological protocol for drug selection is based on several assumptions: (l) the tachycardia produced in the laboratory by programmed stimulation is identical to the clinical tachyarrhythmia; (2) the respense to drug therapy in the laboratory, predicts the clinical response: (3) the ability to prevent an electrically induced ventricular tachycardia by drug treatmem predicts the inability of t~e heart to develop ventricular fibrillation, especially if an i~hemic episode is superimposed upon a vulnerable substrate. Thus, one is not certain that Ihe prevention of electrically-induced arrhvthmias by drug therapy is synonym,.~us w~th the prevention of sudden coronary death. Whereas the first and second assumptions may have been established, the third has not, since an acute ischemic episode is not part of the testing procedure and the true efficacy of a drug intervention can only be determined by Iook~ng at its potential to prevent sudden coronary death; an end-point seldom achieved during provocative testing procedures. It may also be true that a drug which fidls to prevent the initiation of tachyarrhythmia by programmed electrical stimulation may still successfully prevent a spontaneous recurrence. This would be especially true of those agents which accumulate in myocardial tissue over time and show little correlation between concentration of drug in the plasma and therapeutic efficacy, e.g. amiodarone, propranolol and bretyik~.a. Furthermore, the failure to recognize the formation of active metabolites as participating in the overall pharmacological and electrophysiological effects of an intervention could cast additional doubt on the value of a 'therapeutic TiPS -April 1984 plasma concentration' as a guide to adequate therapy unless one is familiar with the metabolic praducts and has approprNate means of quantitating them in plasma.
What needs to be aecomplished?
The previous discussi,m was intended to emphasize the imFortance of the problem of sudden coronary death and to suggest that a pharmacological approach may make a s,ignificant impact upon the mortality rate, if indeed ventricular fibrillation constitutes the terminal electrophysiological event. In reviewing the results of long-term suppressive therapy for the prevention of sudden cardiac death, Lovell 5 stated that 'non-specific long-term prophylactic use of existing drags holds less promise than appeared at one time to be the case. It may be that tolerable drugs which are highly effective in inhibiting ventricular fibrillation when given long-term will be developed, and this is a worthwhile aim'.
Despite the world-wide need for a truly antifibriilatory drug, there has been relatively little effort directed towards this end. At present, the antiarrhythmic drugs available in the USA for chronic management of patients with life-threatening arrhythmias are quinidine, procainamide, disopyramide, propranolol, timolol, metoprolol, and phenytoin. None is considered entirely suitable for long-term prophylactic use in the prevention of sudden coronary death. Of the new agents, namely amiodarone, aprindine, betanidine. tocainide, mexiletine, encainide, meobentine, fleca~de, and pirmenol, none is known specifically to prevent ventricular fibrillation in either the experimental animal or in man. Furthermore, it is most disappointing to note that the newer anti-arrhythmic drugs were not developed specifically for the problem under consideration. There are limited animal data available with respect to these agents and already several are proving to have serious toxic effects associated with their long-term use. This is especially true of amiodarone, which, despite its clinical efficacy as an antifibrillatow agent, has produced significant side-effects, so as to limit its use to the most seriously ill patients.
The approach to finding an effective antifibrillatory drug in contras~ to an anti-arrhythmic drug for the prevention of sudden cardiac death has been one of mere chance alone, and it is doubtful that this 'hit-and-miss" method will ever prove successful. The fact that several pharmacological interventions have TIPS -April 1984 been shown both experimentally and clinicall~ to exert an antifibrilhitory effect 6-" should cause cardiovascular pharmacologists to exert greater effort towards the development of more useful and acceptable agents for the prevention of sudden coronary death. Therefore, if substantial progress is to be made, it will require a greater emphasis upon the preclinical development of pharmacological agents, which, on the basis of invivo and #M'itro electrophysiologicai studies, provide evidence for possessing activity which could allow them to be classified as being antifibrillat~)ry.
Where can one start?
A major problem in designing thempeutic approaches to sudden coronary death has been the limitation of appropriate animal models. The bulk of tbe available data on the electrophysioiogical properties of current anti-arrhvthmic drugs was derived from in-vitro studies on 'normal' cardiac muscle from a variety of animal species. Within recent years some effort has been made to employ ischemically injured myocardial tissue in electrophysiological studies in-vitro.
The description of the mechanisms for arrhythmias and conduction disturbances observed in intact hearts has been based primarily on electrophysiological data obtained in isolated heart muscle or in intact hearts studied many hours or days after isehemic injuD, or in intact animal preparations in which cardiac arrhythmias are induced through the administration of digitalis glycosides or other cardiotoxic-arrhythmogenic agents. Several methods have been developed for producing animal models with chronic myocardial ischemic injury, in which ventricular arrhythmias develop spontaneously or in response to programmed electrical stimulation~(~3. However, these models do not provide an opportunity to examine the electrophysiological events preceding the development of ventricular fibrillation or to study pharmacological interventions for the prevention of life-threatening arrhythmias. In considering the problem of sudden coronary death, it would be advantageous to employ a chronic animal model in which a previous myocardial infarction has left the heart susceptible to the development of reentrant ventricular tachyarrhythmia and in which ventricular fibrillation will occur in response to a new, albeit transient, ischemic insult, insufficient to produce myocardial infarction, but which results in sudden coronary death.
The ideal animal model for the study of pharmacological interventions for the prevention of life-threatening arrhythmias should be based on the knowledge that the incidence of primary,.' ventricular fibrillation is maximal in the first few minutes after an acute ischemic event and thereafter decays exponentially. and that the majority of patients have ventricular fibrillation because of coronary. artery disease, but without acute myocardial infarction as the precipitating event.
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Our laboratory has recently described a conscious canine model ¢~ which is susceptible to the induction of ventricular tachyarrh)¢hmias by programmed electrical stimulation and which possesses the characteristics stated above so that ventricular fibrillation (sudden coronary death) develops in response to a transient ig'hemic event which is superimposed on a ,, .~ntricular myocardium with a previous history, of ischemic in jut" (Fig. 1) . We have been able to demonstrate that disorganization of the cardiac rhythm and the development of ventrieular fibrillation in response to transient regiotml ischemia is unlikely to occur in the absence of previous mxocardial ischemic injury, su~.zesting that disorganization of the cardiac rh~lhm is more likely to t~.'cur in a ventncle which serves as a proper substrate for initiating and maintaining a rhythm callable of degenerating into ventncular fibrillation.
The mode: permits one to demunstrate the existence of c,_,nduction deicers in the epicardium of the infarcted myocardial region, suggesting that a reentrant mechanism is responsible for the tachvarrhvthmias x~hich occur in response to programmed electrical stimulation. Thus. the animal model in which the heart has beea subjected to a pre,,-ious infarction exhibits man~ similar electrophysiological charactenstic:~ to the human post-infarcted heart. It is susceptible to the induction of ,~entncular tachycardia by provt~ative electrical stimulation and it can develop ventriculai: fibrillation as a result of a superimposed transient ischemic evem (Fig. t) . In our laboratory, untreated control animals have a ~1% incidence of "sudden coronary, death'. Pretreatment with bretylium ~s, pranolium ~t', amiodarone.
1001"
~LIN[ iN- IO) or nadolol~7 provides significant protection (40--80%) from ventricular fibrillation in animals subjected to the test procedure (Fig. 2) . Ouinidine. however. given in dosages which achieved plasma concentrations equivalent to those used din:ically, was without a protective action ts. Furthermore, we could not demonstrate a correlation between the ability of a drug to prevent ventricular fib~lation and to suppress induction of ven'tricular tachycardia by programmed electrical stimulation. This was particularly true with respect to amiodarone. On the other hand, quinidine prevented t|:e induction of ventricular arrhythmias by programmed electrical stimulation, bm was without benefit in preventing ventricular fibrillation in our animal rm~lel of sudden coronary death.
We recognize the difficulty in extrapolating from the animal experiment to the clinical situation of sudden coronexy death in man. However, it has become obvious that most anti-arrhythmi¢ ~rugs h~r,,e been, or are evaluated using /nv/tro or in-vivo models which have littie, if any, relationship to the clinical pathophysiological situation associated with sudden coronary death. Thus, animal models such as the one being used in our laboratory should provide a new approach to the predinicai assessment of pharmacological interventions intended specifically four the prevention of ventriodar fibrillation and the prevention of sudden coronary deaih. The final analysis of a drug's potential worth will depend, as usual, upon appropriate clinical testing in patients who are at risk of developing sudden and unexpected life-threatening arrhythmias and/or ventricular fibrillation, rather than employing the more expedient and less dependable approach of ,evaluating new agents for their ability to reduce the frequency and/or complexity of ventricular premature depolarizations.
Substantial pro~ess has been made in recent years with respect to identifying subsets of patients who are at risk of sudden coronary death. Both surgical and electrical means of preventing sudden coronary death in the. most difficultto-manage patient groups have been attempted with impressive results. However, there continues to exist a need for an increased priority to the development 
